Navigation Links
Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
Date:11/8/2011

rket basis in 2012 and 2013. Amylin will work with Lilly on all plans for markets outside the U.S. during the transition period and will guarantee that Lilly does not experience losses on exenatide-related activities during that period, up to a total cap of $60 million.

The Amylin and Lilly alliance resulted in several innovations in the diabetes market. These innovations include the 2005 launch of the first-in-class GLP-1 receptor agonist, BYETTA, a treatment that has been used by 1.8 million patients worldwide, and submission of the first once-weekly GLP-1 receptor agonist, BYDUREON, an investigational medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. BYDUREON received marketing authorization in the European Union in June 2011 and is currently under review in the U.S., with a Prescription Drug User Fee Action (PDUFA) date of January 28, 2012. Amylin will continue to evolve the GLP-1 market with the exenatide franchise through the development of a pen device for BYDUREON and the exenatide monthly suspension program.

Amylin to Host Investor Conference Call

Amylin will host a conference call to discuss the transition of the exenatide franchise today at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals, will lead the call. A slide presentation accompanying the conference call will be available through the "Investors" section of Amylin's corporate website at www.amylin.com.

The call will be webcast live through the "Investors" section of Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.amylin.com approximately 15 minutes prior to the call to register, download and install any necessary audio software. For those without access to the Inte
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process
2. Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership
3. Lilly Provides Update on 2011 Financial Guidance Due to Xigris Withdrawal
4. Prasco® Selected as Eli Lilly and Companys Authorized Generics Partner
5. Lilly Reports Third-Quarter 2011 Results
6. Lilly Declares Fourth-Quarter 2011 Dividend
7. Lilly Announces Changes in Senior Management
8. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
9. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
10. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
11. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... LAS VEGAS , March 26, 2015 Zimmer ... of a new mobile app designed to serve as a ... Hyaluronate product. For those experiencing knee ... valuable information about the causes of knee pain and helps ... Hyaluronate as a safe and simple non-surgical treatment option. For ...
(Date:3/26/2015)... Californie, 26 mars 2015 Finesse Solutions ... conçu pour les innovateurs, visionnaires et cadres de ... conférence d,une durée de deux jours proposée exclusivement ... dans le centre ville de San ... 2015. Il s,agira d,un forum destiné aux leaders ...
(Date:3/26/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx") today ... from the Israeli patent office with claims for administering ... damage caused by an increase in blood flow, as ... after a blockage causing a heart attack or in ... can be caused to the heart attack or stroke ...
Breaking Medicine Technology:Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate 2Finesse Solutions annonce l'événement Cellworld 2015 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3
... NESHER, Israel, April 21 NanoVibronix, a ... surface ultrasound waves,announced that its novel device ... claims of wound healing. PainShield is the ... waves for therapeutic,treatment of wounds. The innovative ...
... - Preclinical Studies Highlight the Ability of PS-Targeting ... Tumors by Changing the Tumor Microenvironment and Mobilizing ... Studies Confirm Peregrine,s PS-Targeting Antibodies Stimulate Dendritic Cell ... of Macrophages to Tumors -DENVER and TUSTIN, Calif., ...
Cached Medicine Technology:NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device 2Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 2Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 3Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 4Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 5Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 6Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies 7
(Date:3/26/2015)... Md. (PRWEB) March 26, 2015 ... than $11.3 billion in 2014, according to an ... , The Annapolis-based healthcare real estate (HRE) data ... board members and two new Gold-Level Partners: Harrison ... Investment Services. , MOB transactions still going strong, ...
(Date:3/26/2015)... 2015 Pacific Medical LLC, the leader ... be featured on Innovations with Ed Begley Jr, which ... The episode will repeat on local cable channels ... Pacific Medical home page at: http://www.pacificmedicalsupply.com . ... is reassuring to trust the integrity of the medical ...
(Date:3/26/2015)... On March 5, 2015, Portland Trail ... for the season with a torn Achilles tendon in ... Blazers were competing against Dallas, and was confirmed via ... Silva, M.D., who has treated many professional athletes, voiced ... could be prevented. , "Part of the problem ...
(Date:3/26/2015)... In the key developed markets, the hypertension market value ... to decrease through 2020 at a negative CAGR (0.9%) to ... to 2017 at a 2.6% CAGR and a decline thereafter. ... surging penetration of fixed-dose combination drugs like Azor, Amturnide, Exforge ... and Tekamlo), a hike in the prevalence population to 190 ...
(Date:3/26/2015)... March 26, 2015 In preparation for ... Fitness Revolution, founded by Samir Becic, has issued ... own personal health and fitness, as well as their ... The list includes Sen. Ted Cruz, who has officially ... as all other politicians who have shown interest in ...
Breaking Medicine News(10 mins):Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 2Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 3Health News:Medical Real Estate Sales Topped $11.3 Billion in 2014 4Health News:Pacific Medical Featured on the Discovery Channel 2Health News:Pacific Medical Featured on the Discovery Channel 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3
... they are admitted to hospital may be one way to ... today’s BMJ. ,Recent data published by the Health ... 7,000 inpatients have MRSA infections and more than 50,000 inpatients ... of C difficile rose by 5.5% in 2006, whereas MRSA ...
... by blocking the lifesaving effects of aspirin//, a new study ... monstrous," Michael Farkouh, director of clinical trials at Mount Sinai ... ,“Ibuprofen is relatively safe except when we give it ... Farkouh says. "But when given with aspirin, we do we ...
... couple of months, 100,000 doses of the country's first vaccine ... developed it has found no takers //and the expiry date ... year that the High Security Animal Disease Laboratory (HSADL) here ... about 100,000 doses of the vaccine, each costing just 27 ...
... mammograms are more likely to interpret a benign growth ... and experience," and CAD systems do not help detect ... systems use complex algorithms to identify "suspicious" areas of ... which cost $50,000 to $175,000, were approved by FDA ...
... The Food and Drug Administration (FDA) today warned consumers ... Chews and Dog Chews manufactured// and distributed by T.W. ... have the potential to be contaminated with Salmonella, which ... if there is cross contamination, in people, especially children, ...
... Foundation on Wednesday announced that it will spend $500 ... address childhood obesity//, particularly targeting minority children, who are ... ,Nearly 25 million children under age 18 are considered ... medical expenses, according to the foundation. ,The ...
Cached Medicine News:Health News:Ibuprofen Risky for Heart Patients? 2Health News:100,000 Bird Flu Vaccine Doses to Be Destroyed 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: